MULTIPLE MYELOMA

CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.

The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Siddhartha Ganguly, MD, reviewed the case of a 51-year-old man with standard-risk multiple myeloma.

During a virtual Case Based Peer Perspective event, Cristina Gasparetto, MD, discussed the case of a geriatric male diagnosed with stage II multiple myeloma.

The FDA granted approval to the combination of daratumumab plus carfilzomib and dexamethasone as treatment of adult patients with relapsed or refractory multiple myeloma who have received up to 3 prior lines of therapy.

As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient.

C. Ola Landgren, MD, PhD, discusses the use of chimeric antigen receptor T cells and CAR natural killer cells in the multiple myeloma setting.

A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.

Kenneth C. Anderson, MD, discusses the therapies for patients who have multiple myeloma and have developed drug resistance.

The FDA granted approval to belantamab mafodotin-blmf for the treatment of patients with relapsed or refractory multiple myeloma who previously received treatment with at least 4 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

In an interview with Targeted Oncology, Hearn Jay Cho, MD, PhD, and Irene M. Ghobrial, MD, both discussed the importance of the CureCloud study for the multiple myeloma community, and their hopes for what this study can achieve for myeloma patients and their physicians.

In an interview with Targeted Oncology, C. Ola Landgren, MD, PhD, discussed the development of CAR T-cell therapy in the treatment landscape of multiple myeloma.

Updated findings from phase 3 APOLLO show an improvement in progression-free survival with daratumumabe plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone alone.

A Biologics License Application has been submitted to the FDA for the use of idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.

The FDA has accepted the supplemental New Drug Application seeking approval of selinexor as treatment of patients with multiple myeloma following at least 1 prior line of therapy.